|
|
Highlights from PAS: Rare Disorders - Don't Miss a Treatable Disease
Target Audience
This activity is designed to meet the educational needs of neonatologists, pediatricians, geneticists, family practice, registered nurses, nurse practitioners, physician assistants, genetic counselors, and other HCPs who wish to improve their knowledge and competence in identifying and managing patients with treatable rare disorders through NBS as well as other measures.
Program Overview
This activity will feature clinical cases where newborn screening (NBS) identified a t... |
|
|
Navigating the Rapidly Evolving Classification and Treatment Landscape of Secondary AML Subtypes: Modeling Best Practices for Early Identification and Individualized Care
Are you optimally treating secondary AML subtypes per latest evidence on selection of therapies? To optimize treatment, clinicians must not only have current knowledge of the up-to-date classification and risk stratification strategies, but the operational frameworks to effectively translate this latest evidence into treatment selection practices. Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create your own action plan to ensu... |
|
|
Nonspecific Symptoms in Primary Care: Can You Diagnose These Patients?
When your patient presents with nonspecific symptoms such as shortness of breath, fatigue, and dizziness, could it be an indication of a more serious disease? Put your skills to the test! In just 15 minutes, navigate through real-world cases to see if you can correctly diagnose each patient. Diagnostic conclusions are revealed after reviewing all cases. Hear faculty insights on the implications of learner decisions along with rationales for appropriate next steps to aid in making a final diagn... |
|
|
Common Nonspecific Symptoms at Presentation: Can You Diagnose This Patient?
When your patient presents with nonspecific symptoms such as shortness of breath, fatigue, and dizziness, could it be an indication of a more serious disease? Put your skills to the test! In just 15 minutes, navigate through real-world cases to see if you can correctly diagnose each patient. Diagnostic conclusions are revealed after reviewing all cases. Hear faculty insights on the implications of learner decisions along with rationales for appropriate next steps to aid in making a final diagn... |
|
|
Psoriasis Prime Time: The Role of TYK Inhibition in Psoriasis
Target Audience
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.
Program Overview
In this edition of Psoriasis Prime Time, the faculty reviews the unique mechanism of action for allosteric tyrosine kinase 2 (TYK2) inhibitors compared with Janus kinase inhibito... |
|
|
29th Annual Hypertension, Diabetes & Dyslipidemia Conference
Combine medical education and southern charm at the 29th Annual Hypertension, Diabetes, & Dyslipidemia Conference, happening from June 18-20, 2025, at the Hyatt Regency in Savannah, GA. Immerse yourself in a dynamic CME-accredited program, garnering 15.25 credits, designed to address the complexities of diabetes, hypertension, and dyslipidemia. Join healthcare professionals in the historic setting of Savannah, where centuries-old tradition will meet modern clinical insights, creating a tru... |
|
|
Acute Myeloid Leukemia: Targeting Key Clinical Issues for Oncology Nurses
The landscape of AML treatment is evolving, and newer targeted agents may improve outcomes for selected subgroups of patients. Activity goal considerations for the nurse/NP when participating in this activity:
Treatment decision making with incorporation of cytogenetic and molecular testing
Considerations in the care of a patient receiving therapy for AML related to nursing care and side effect management
Psychosocial considerations and resources for a patient with AML
Oncology nurses an... |
|
|
Keeping Up with the Evolving Treatment Landscape for Advanced/Metastatic Gastric/GEJ Cancer: Modeling Center of Excellence Practices
Are you optimally treating your patients with gastric/gastroesophageal junction (GEJ) cancers per the latest evidence on selection of therapies? Despite recent advancements in diagnosis of gastric/GEJ cancer, most cases are detected at advanced stages, resulting in poor outcomes. But advances have identified biomarkers that can offer more precise diagnostic and therapeutic approaches for gastric/GEJ cancer patients. In addition to HER2 and PD-L1 status, microsatellite instability (MSI) status... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology and family practice. Other members of the care team may also participate.
Program Overview
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subt... |
|
|
Multidisciplinary Team Essentials on CMV Prevention, Surveillance, and Treatment Optimization in the Transplant Setting
The role of the multidisciplinary transplant team has expanded considerably over the past decade to keep pace with advances in the field and to address long-term care of transplant recipients. Despite these advances, breakthrough cytomegalovirus (CMV) infections and development of refractory and resistant CMV infections cause significant complications post-transplant. To lessen patient burden and improve survival outcomes, optimal introduction of anti-CMV drugs, both prophylactically and thera... |
|
|
Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden: A Care Team Forum®
Target Audience
Transplant, infectious disease, internal medicine, nephrologists, primary care, pharmacy clinicians, advanced practice providers, and surgeons managing patients with CMV
Program Overview
Cytomegalovirus (CMV) is one of the most common infectious complications in solid organ transplant (SOT) recipients. During this activity, the faculty will discuss best practices for prevention and treatment of CMV post-transplant and provide clinical pearls for managing difficult-to-tr... |
|
|
Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis
In this on-demand activity, Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, learn from expert faculty, Jeanne Palmer, MD and Jennifer Andres, APRN, FNP, MSN as they discuss Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, to effectively identify how JAK inhibitors and emerging treatments for myelofibrosis (MF) can optimize clinical outcomes and patient quality of life (QOL).
Gain expe... |
|
|
PEERx - Ethics Module 6: Preparing Pharmacy For The Next Crisis
This Educational Activity is provided by Pharmacy Ethics, Education, and Resources (PEER) and is designed to educate healthcare professionals on ethics to improve patient safety.
The emergence of the COVID-19 virus in 2020 plunged the world into an unprecedented pandemic. Pharmacists found themselves at the forefront of this global health emergency, facing it with minimal preparation and guidance. With existing emergency plans proving ineffective during a worldwide shutdown, this initiat... |
|
|
Psoriasis With Scalp Involvement in a Patient With Skin of Color
Target Audience
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.
Program Overview
This case will discuss the treatment of psoriasis in patients with skin of color, highlighting the challenges of treating scalp psoriasis. The faculty will review the mechanism o... |
|
|
Psoriasis Prime Time: TYK Inhibition in Hard-to-Treat Psoriasis
Target Audience
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.
Program Overview
In this edition of Psoriasis Prime Time, the faculty reviews the use of allosteric tyrosine kinase 2 (TYK2) inhibitors in the treatment of hard-to-treat psoriasis, including the ... |
|
|
Can You Diagnose this Patient with Edema, Pain, Abdominal Swelling, and/or Fatigue?
When your patient presents with symptoms such as edema, fatigue, and abdominal pain, what might you first suspect and can you reach the right diagnosis? Put your diagnostic skills to the test! In just 15 minutes, navigate through real-world cases and upon completion, hear faculty insights on the implications of your decisions along with rationales for appropriate next steps to aid in making a final diagnosis, as well as evidence-based treatment strategies. Apply the latest scientific evidence ... |
|
|
How the Patient Experience Should Inform Treatment Selection: Reframing Expectations in EoE for HCPs and Patients
Eosinophilic esophagitis (EoE) has been steadily increasing in prevalence and incidence over the past three decades. Today, EoE has evolved from a rare case-reportable condition to a disease that is commonly encountered in the clinic and endoscopy suite and is a major cause of upper gastrointestinal morbidity and increasing healthcare costs.
Delays in diagnosis persist and management of the disease can be complex. While significant advances in the treatment of EoE have been made, studies s... |
|
|
Management of Metastatic Colorectal Cancer
Stacey Cohen, MD, explores the significance of molecular profiling and tumor markers in personalizing immunotherapy for metastatic colorectal cancer. She also delves into the evolving landscape of targeted therapies, discussing the nuances and considerations of different options to optimize patient outcomes. |
|
|
Making The Call in Lower-Risk MDS Exploring Treatments That Improve Outcomes & Decrease Transfusion Burden
Myelodysplastic syndromes (MDSs) are among the most common hematologic malignancies and are characterized by their risk of progression to acute leukemia. Although patients with lower-risk MDS (LR-MDS) have longer life expectancies compared to those with high-risk disease, their disease course is not without challenges. In fact, symptoms related to anemia are very common in this population and lead to poor quality of life. Fortunately, therapies are now available to treat the anemia associated ... |
|
|
Recognizing and Confirming Potential ATTR in Your Patients
Target Audience
This activity is designed to meet the educational needs of physicians, allied health practitioners, and students interested in complex cardiovascular and thoracic conditions and those who care for patients with ATTR.
Program Overview
This activity will cover early diagnosis and intervention for transthyretin amyloidosis (ATTR), which is critical, yet does not occur, typically as a consequence of the rarity and heterogeneity of the disease and limited awareness on the part ... |
|
|
Navigating the Evolving Standards of Newly Diagnosed Multiple Myeloma Treatment: Exploring the Evidence on New Combination Strategies
ACTIVITY DESCRIPTION
The goal of treatment for newly diagnosed multiple myeloma (NDMM) patients is achieving the deepest possible remission, which typically involves aiming for minimal residual disease negativity. Frontline therapy for NDMM is evolving to include novel induction regimens with anti-CD38 antibodies, which have been shown to yield improved depth of response after induction. These new frontline treatments vary in induction regimen composition and use of transplant, consolidation,... |
|
|
Podcast: Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractor... |
|
|
Bridging the Health Gaps in Hereditary Angioedema: Demystifying Disparities, Enhancing Quality of Life, and Implementing Effective Prophylactic Solutions
Hereditary angioedema (HAE) is a rare, life-threatening disorder characterized by recurrent, unpredictable episodes of bradykinin-induced swelling. In this presentation, Dr. Marc Reidl, Clinical Director of the US Hereditary Angioedema Association (HAEA) Angioedema Center, reviews multiple underrecognized factors that contribute to health disparities among patients with HAE, including delays in diagnosis and multifaceted differences among racial and ethnic groups, socioeconomic status levels, ... |
|
|
Best of ACTHIV®: HIV 101 " Pathogenesis
Description:
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2023 conference for the frontline HIV care team, this activity will describe HIV infection and viral dynamics, define how viral dynamics impact management of antiretroviral therapy, and describe current progress in area of HIV cure/remission
Learning Objectives
After participating in the activity, learners should be better able to:
Describe HIV infection and viral d... |
|
|
Best of ACTHIV® 2024: HIV the Basics"Primary Care in HIV
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2024 conference for the frontline HIV care team, this activity will focus on best practices for a new patient intake for someone diagnosed with HIV, including asking relevant medical, social and historical information, and ensuring appropriate lab tests, diagnostic imaging and vaccinations based on the history taken.
Learning Objectives
Complete a new patient intake for someone diagno... |
|
|
Best of ACTHIV® 2024: Beyond Viral Suppression: How Addressing Mental Health Directly Reduces Morbidity and Mortality in People with HIV
Description
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2024 conference for the frontline HIV care team, this activity will focus on identifying causes of death that are direct outcomes of poor mental health among PWH, and provide guidance for the care team to better enable them to address mental health problems as a component of all HIV-related prevention, care and treatment approaches.
Learning Objectives
Identify three ca... |
|
|
Best of ACTHIV® 2024: Balancing Management of Multimorbidity and Polypharmacy in Aging PWH
Description
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2024 conference for the frontline HIV care team, this activity will focus on how polypharmacy applies to people with HIV, complications of polypharmacy, and how care teams can work together to identify patients who might benefit from deprescribing.
Learning Objectives
Describe polypharmacy and how it applies to People with HIV (PWH)
List complications of polypharma... |
|
|
Best of ACTHIV® 2024: Aging with HIV and the Challenge of Multimorbidity
Description
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2024 conference for the frontline HIV care team, this activity will focus on multimorbidity and its implications in the care of older people with HIV as well as approaches to screening for and managing multimorbidity and aging-related syndromes for the care team.
Learning Objectives
Recognize the changing demographics of HIV and comorbidity burden
Explain multimorb... |
|
|
Best of ACTHIV® 2024: Hypertension and Renal Disease in People with HIV
Description
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2024 conference for the frontline HIV care team, this activity will focus on epidemiology of, and risk factors for renal disease in PWH, evaluating renal function, improving management of hypertension, and working as a team to optimize ARV decisions in PWH and renal dysfunction.
Learning Objectives
Describe the epidemiology of, and risk factors for renal disease in HIV
... |
|
|
Best of ACTHIV® 2024: Sexually Transmitted Infections: Epidemiology and Missed Opportunities
Description
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2024 conference for the frontline HIV care team, this activity will focus on current trends of common nationally notifiable STIs, potential challenges to diagnosing and treating chlamydia, gonorrhea, and syphilis, and how teams can apply knowledge of screening and treatment of syphilis in pregnant persons to prevent congenital syphilis.
Learning Objectives
Describe the ... |
|
|
Inherited Retinal Diseases: Navigating the Future of Diagnostics and Emerging Therapies
The differential diagnosis and workup of a suspected inherited retinal disease (IRD) can be challenging, requiring the expertise of the multidisciplinary healthcare team. Guidelines released in 2022 by the American Academy of Ophthalmology provide recommendations and clinical genetic assessments for patients with IRDs. Genetic counseling is essential to help patients understand the genetic test results, their implications for prognosis, family planning, and therapeutic decisions. Genetic testi... |
|
|
nAMD and DME: Novel Treatment Plans to Prioritize Real-World Visual Improvements
Frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapies can significantly improve visual and anatomical outcomes for many patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, the requisite high number of treatments often leads to less-than-ideal results compared to outcomes reported in major clinical trials, largely due to the demanding treatment schedule. Adopting tailored treatment plans, along with ... |
|
|
Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies
In this Hematology Dialogues, Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies, participants will learn about the epidemiology and burden of Epstein-Barr Virus-positive (EBV+) and post-transplant lymphoproliferative disorders (PTLD), differentiate between current and emerging prognostic scoring systems for EBV+ and PTLD to inform treatment decisions, and evaluate the latest clinical evidence of emerging treatment options ... |
|
|
Nutraceuticals for Dry Eye: Dispelling the Dogma and Embracing the Data
Dry eye disease is a common yet frequently overlooked condition that significantly affects quality of life. Despite an estimated global prevalence of up to 50%, DED is often underdiagnosed and inadequately managed. To limit the burden of DED, it is crucial for clinicians to be adept at recognizing risk factors and making accurate diagnoses. In addition, as treatment options expand to include clinically proven nutraceuticals, it is imperative that clinicians stay abreast of the latest clinical ... |
|
|
Can You Diagnose This Patient With Impaired Balance and Paresthesia?
When your patient presents with symptoms such as impaired balance and paresthesia, what might you first suspect and can you reach the right diagnosis? Put your diagnostic skills to the test! In just 15 minutes, navigate through real-world cases and upon completion, hear faculty insights on the implications of your decisions along with rationales for appropriate next steps to aid in making a final diagnosis, as well as evidence-based treatment strategies. Apply the latest scientific evidence in... |
|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|
|
Advances in Recurrent/Metastatic Nasopharyngeal Carcinoma: Immunotherapy and Biomarkers
Target Audience
This activity was developed for medical oncologists, head and neck surgeons, radiation oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients diagnosed with metastatic nasopharyngeal carcinoma (NPC).
Program Overview
Greater understanding of the tumor microenvironment of nasopharyngeal carcinoma (NPC) has led to the introduction of immunotherapy into the NPC treatment landscape. Incorporating immunotherapy has change... |
|
|
Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche i... |
|
|
Halting the Spiral in Worsening Heart Failure: A Virtual Patient Simulation.
Target Audience
The intended audience for this activity includes cardiologists and cardiology advanced practice providers involved in the management of patients with heart failure.
Program Overview
Despite advances in guideline-directed medical therapy, patients with heart failure with reduced ejection fraction (HFrEF) often experience worsening symptoms, leading to increased hospital admissions and a higher risk of adverse outcomes. Halting the Spiral in Worsening Heart Failure: A Virtua... |
|
|
Cleveland Clinic Hospital Medicine
Cleveland Clinic Hospital Medicine features a comprehensive review of the most common and relevant conditions seen in the inpatient setting. A globally renowned faculty addresses the application of new evidence, interprets current guidelines and provides management strategies which can improve the quality of medical care. All physicians, nurses and physician assistants treating hospitalized patients will benefit from this thoughtful assessment of best practices in this critical area of medici... |
|
|
Ultrasound Guided Vascular Access - Blended Course
The Ultrasound Guided Vascular Access Blended Training Course is planned in accordance with the current Agency for Healthcare Research and Quality (AHRQ) and ACEP guidelines and provides participants a strong foundation to perform central and peripheral line techniques in an emergency setting. The Blended Education format provides flexibility while saving you time and minimizing travel costs.
Begin with the self-paced online course: Taught by leading emergency medicine ultrasound experts ... |
|
|
Bridging Gaps, Optimizing Treatment in Adults With LC-FAODs
In this 45-minute, case-based, modular activity, Sandra van Calcar, PhD, RD, LD, and Jerry Vockley, MD, PhD, address key topics, including disease presentation, historical treatment, emerging treatment with triheptanoin, and nutritional planning specific to patients with LC-FAODs. Triheptanoin is an odd-carbon MCT designed to bypass the metabolic block in LC-FAODs, recently approved as an alternative treatment option. The faculty discuss the safety and efficacy of triheptanoin and their real-w... |
|
|
Beyond the Guidelines for CMV: Clinical Perspectives on Challenging Cases Post-Transplant: A Clinical Forum®
Target Audience
Infectious disease, transplantation, internal medicine, and nephrology clinicians
Program Overview
Cytomegalovirus (CMV) is a prevalent and potentially life-threatening viral infection in transplant recipients. CMV management in this high-risk population continues to evolve with updated guidelines and newer, less toxic antiviral therapy.
During this activity, faculty will discuss state-of-the-art strategies for preventing and treating CMV in transplant patients, sharing... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Evolving Treatment Paradigms in HR+/HER2- Early Breast Cancer: Advancing Equitable Care in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer accounts for up to 70% of all breast cancer cases. In recent years, therapies such as CDK4/6 inhibitors, PARP inhibitors, and novel endocrine therapies have been ... |
|
|
Cleveland Clinic Primary Care + (online streaming & flash drive formats)
Cleveland Clinic Primary Care + highlights the latest therapies, procedures and diagnostics in primary care, women’s health and behavioral medicine. This best practices review addresses the educational needs of primary care clinicians who must stay abreast of current research and treatments in a wide range of disciplines. Physicians, nurses and physician assistants will all benefit from Cleveland Clinic’s expert analysis of essential subjects in primary care.
Worth 21 AMA PRA Catego... |
|